Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 99

1.

Connection domain mutations during antiretroviral treatment failure in Mali: frequencies and impact on reverse transcriptase inhibitor activity.

Maiga AI, Penugonda S, Katile D, Diallo F, Fofana DB, Berzins B, Maiga MY, Sylla A, Traore HA, Marcelin AG, Calvez V, Tounkara A, Bellosillo N, Murphy R, Taiwo B.

J Acquir Immune Defic Syndr. 2012 Nov 1;61(3):293-6. doi: 10.1097/QAI.0b013e31826a4b34.

PMID:
22828721
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance.

Yap SH, Sheen CW, Fahey J, Zanin M, Tyssen D, Lima VD, Wynhoven B, Kuiper M, Sluis-Cremer N, Harrigan PR, Tachedjian G.

PLoS Med. 2007 Dec;4(12):e335.

PMID:
18052601
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Clinical relevance of substitutions in the connection subdomain and RNase H domain of HIV-1 reverse transcriptase from a cohort of antiretroviral treatment-naïve patients.

Hachiya A, Shimane K, Sarafianos SG, Kodama EN, Sakagami Y, Negishi F, Koizumi H, Gatanaga H, Matsuoka M, Takiguchi M, Oka S.

Antiviral Res. 2009 Jun;82(3):115-21. doi: 10.1016/j.antiviral.2009.02.189. Epub 2009 Feb 21.

PMID:
19428602
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Connection domain mutations in HIV-1 reverse transcriptase do not impact etravirine susceptibility and virologic responses to etravirine-containing regimens.

Gupta S, Vingerhoets J, Fransen S, Tambuyzer L, Azijn H, Frantzell A, Paredes R, Coakley E, Nijs S, Clotet B, Petropoulos CJ, Schapiro J, Huang W, Picchio G.

Antimicrob Agents Chemother. 2011 Jun;55(6):2872-9. doi: 10.1128/AAC.01695-10. Epub 2011 Apr 4.

PMID:
21464253
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Connection domain mutations in treatment-experienced patients in the OPTIMA trial.

Dau B, Ayers D, Singer J, Harrigan PR, Brown S, Kyriakides T, Cameron DW, Angus B, Holodniy M.

J Acquir Immune Defic Syndr. 2010 Jun;54(2):160-6. doi: 10.1097/QAI.0b013e3181cbd235.

PMID:
20130473
[PubMed - indexed for MEDLINE]
6.

Impact of CRF01_AE-specific polymorphic mutations G335D and A371V in the connection subdomain of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) on susceptibility to nucleoside RT inhibitors.

Tanuma J, Hachiya A, Ishigaki K, Gatanaga H, Lien TT, Hien ND, Kinh NV, Kaku M, Oka S.

Microbes Infect. 2010 Dec;12(14-15):1170-7. doi: 10.1016/j.micinf.2010.08.003. Epub 2010 Aug 14.

PMID:
20713171
[PubMed - indexed for MEDLINE]
7.

Low-frequency K103N strengthens the impact of transmitted drug resistance on virologic responses to first-line efavirenz or nevirapine-based highly active antiretroviral therapy.

Geretti AM, Fox ZV, Booth CL, Smith CJ, Phillips AN, Johnson M, Li JF, Heneine W, Johnson JA.

J Acquir Immune Defic Syndr. 2009 Dec;52(5):569-73. doi: 10.1097/QAI.0b013e3181ba11e8.

PMID:
19779307
[PubMed - indexed for MEDLINE]
8.

A376S in the connection subdomain of HIV-1 reverse transcriptase confers increased risk of virological failure to nevirapine therapy.

Paredes R, Puertas MC, Bannister W, Kisic M, Cozzi-Lepri A, Pou C, Bellido R, Betancor G, Bogner J, Gargalianos P, Bánhegyi D, Clotet B, Lundgren J, Menéndez-Arias L, Martinez-Picado J; EuroSIDA Study Group.

J Infect Dis. 2011 Sep 1;204(5):741-52. doi: 10.1093/infdis/jir385.

PMID:
21844300
[PubMed - indexed for MEDLINE]
Free Article
9.

Panel of prototypical recombinant infectious molecular clones resistant to nevirapine, efavirenz, etravirine, and rilpivirine.

Balamane M, Varghese V, Melikian GL, Fessel WJ, Katzenstein DA, Shafer RW.

Antimicrob Agents Chemother. 2012 Aug;56(8):4522-4. doi: 10.1128/AAC.00648-12. Epub 2012 Jun 4.

PMID:
22664973
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Phenotypic characterization of drug resistance-associated mutations in HIV-1 RT connection and RNase H domains and their correlation with thymidine analogue mutations.

Lengruber RB, Delviks-Frankenberry KA, Nikolenko GN, Baumann J, Santos AF, Pathak VK, Soares MA.

J Antimicrob Chemother. 2011 Apr;66(4):702-8. doi: 10.1093/jac/dkr005. Epub 2011 Jan 26.

PMID:
21393163
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Combinations of mutations in the connection domain of human immunodeficiency virus type 1 reverse transcriptase: assessing the impact on nucleoside and nonnucleoside reverse transcriptase inhibitor resistance.

Gupta S, Fransen S, Paxinos EE, Stawiski E, Huang W, Petropoulos CJ.

Antimicrob Agents Chemother. 2010 May;54(5):1973-80. doi: 10.1128/AAC.00870-09. Epub 2010 Mar 1.

PMID:
20194692
[PubMed - indexed for MEDLINE]
Free PMC Article
12.

Connection subdomain mutations in HIV-1 subtype-C treatment-experienced patients enhance NRTI and NNRTI drug resistance.

Delviks-Frankenberry KA, Lengruber RB, Santos AF, Silveira JM, Soares MA, Kearney MF, Maldarelli F, Pathak VK.

Virology. 2013 Jan 20;435(2):433-41. doi: 10.1016/j.virol.2012.09.021. Epub 2012 Oct 13.

PMID:
23068886
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Combination of V106I and V179D polymorphic mutations in human immunodeficiency virus type 1 reverse transcriptase confers resistance to efavirenz and nevirapine but not etravirine.

Gatanaga H, Ode H, Hachiya A, Hayashida T, Sato H, Oka S.

Antimicrob Agents Chemother. 2010 Apr;54(4):1596-602. doi: 10.1128/AAC.01480-09. Epub 2010 Feb 1.

PMID:
20124001
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Resistance patterns selected by nevirapine vs. efavirenz in HIV-infected patients failing first-line antiretroviral treatment: a bayesian analysis.

Ngo-Giang-Huong N, Jourdain G, Amzal B, Sang-a-gad P, Lertkoonalak R, Eiamsirikit N, Tansuphasawasdikul S, Buranawanitchakorn Y, Yutthakasemsunt N, Mekviwattanawong S, McIntosh K, Lallemant M; Program for HIV Prevention and Treatment (PHPT) study group.

PLoS One. 2011;6(11):e27427. doi: 10.1371/journal.pone.0027427. Epub 2011 Nov 23.

PMID:
22132100
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

HIV-1 reverse transcriptase connection domain mutations: dynamics of emergence and implications for success of combination antiretroviral therapy.

von Wyl V, Ehteshami M, Demeter LM, Bürgisser P, Nijhuis M, Symons J, Yerly S, Böni J, Klimkait T, Schuurman R, Ledergerber B, Götte M, Günthard HF; Swiss HIV Cohort Study.

Clin Infect Dis. 2010 Sep 1;51(5):620-8. doi: 10.1086/655764.

PMID:
20666602
[PubMed - indexed for MEDLINE]
Free Article
16.

Resistance profile and cross-resistance of HIV-1 among patients failing a non-nucleoside reverse transcriptase inhibitor-containing regimen.

Delaugerre C, Rohban R, Simon A, Mouroux M, Tricot C, Agher R, Huraux JM, Katlama C, Calvez V.

J Med Virol. 2001 Nov;65(3):445-8.

PMID:
11596076
[PubMed - indexed for MEDLINE]
17.

Etravirine and rilpivirine resistance in HIV-1 subtype CRF01_AE-infected adults failing non-nucleoside reverse transcriptase inhibitor-based regimens.

Bunupuradah T, Ananworanich J, Chetchotisakd P, Kantipong P, Jirajariyavej S, Sirivichayakul S, Munsakul W, Prasithsirikul W, Sungkanuparph S, Bowonwattanuwong C, Klinbuayaem V, Petoumenos K, Hirschel B, Bhakeecheep S, Ruxrungtham K.

Antivir Ther. 2011;16(7):1113-21. doi: 10.3851/IMP1906.

PMID:
22024527
[PubMed - indexed for MEDLINE]
18.

Positive and negative drug selection pressures on the N348I connection domain mutation: new insights from in vivo data.

Price H, Asboe D, Pozniak A, Gazzard B, Fearnhill E, Pillay D, Dunn D; UK Collaborative Group on HIV Drug Resistance; UK Collaborative HIV Cohort Study.

Antivir Ther. 2010;15(2):203-11. doi: 10.3851/IMP1511.

PMID:
20386075
[PubMed - indexed for MEDLINE]
19.

Zidovudine (AZT) monotherapy selects for the A360V mutation in the connection domain of HIV-1 reverse transcriptase.

Brehm JH, Scott Y, Koontz DL, Perry S, Hammer S, Katzenstein D, Mellors JW, Sluis-Cremer N; AIDS Clinical Trials Group Study 175 Protocol Team.

PLoS One. 2012;7(2):e31558. doi: 10.1371/journal.pone.0031558. Epub 2012 Feb 21.

PMID:
22363673
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors.

Brehm JH, Koontz DL, Wallis CL, Shutt KA, Sanne I, Wood R, McIntyre JA, Stevens WS, Sluis-Cremer N, Mellors JW; CIPRA-SA Project 1 Study Team.

Clin Infect Dis. 2012 Sep;55(5):737-45. Epub 2012 May 22.

PMID:
22618567
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk